肝胆道外科研究

肝胆道研究グループは1990年代後半に遺伝子グループとして遺伝子治療を目指した研究を開始しました。

以来、研究内容を肝胆道がん研究、肝胆道がんにおけるバイオマーカー探索・そして近年では大動物を用いた肝臓外科研究など、臨床を意識したテーマで研究を行っています。一方、臨床研究も積極的に行なっており、これまで数多くの報告をしております。

 

多くの大学院生達と共に、肝胆道外科の成績向上を目指して日々研究に邁進しています。

 

研究概要

当グループでは現在、主に以下のような研究を行なっております。

  1. 癌特異的糖代謝に着目した治療抵抗性肝胆道癌の新規治療開発　（楊）
  2. 腫瘍特異的抗体と蛍光の接合化合物を用いた新たな蛍光ガイド手術の確立　（西野）
  3. EDCシステムを利用した多機関共同臨床研究（楊）
  4. 肝胆道癌における予後改善を目指したバイオマーカー探索（楊）
  5. 動物モデルを用いた化学療法関連肝障害の克服（楊・西野）

 

研究グループ所属者名

  • 助教：楊　知明
  • 助教：西野　裕人
  • 研究生：佐藤　元彦
  • 大学院生：堀　佑太郎・栗本　信・高松　雄一・大倉　啓輔

連絡先

  • 楊　知明：tomyoh＊kuhp.kyoto-u.ac.jp
  • 西野　裕人：hnishino＊kuhp.kyoto-u.ac.jp

（連絡する際には＊を＠に変更してください）

 

代表的な研究業績 2018〜2021

筆頭著者は当研究室所属あるいは発表時所属

  1. Learning process of laparoscopic liver resection and postoperative outcomes: chronological analysis of single-center 15-years’ experience. Yoh T, Seo S, Ogiso S, Morino K, Nishio T, Koyama Y, Fukumitsu K, Ishii T, Taura K, Hatano E. Surg Endosc. 2021 Jul 26. doi: 10.1007/s00464-021-08660-2. Online ahead of print.
  2. Identifying Patients Who May Benefit from Liver Resection Compared to Living Donor Liver Transplantation for Hepatocellular Carcinoma Using 18F-FDG PET. Yoh T, Seo S, Taura K, Hamaguchi Y, Ogiso S, Fukumitsu K, Ishii T, Hata K, Kaido T, Nakamoto Y, Uemoto S. World J Surg. 2021 Jul 17. doi: 10.1007/s00268-021-06235-9. Online ahead of print.
  3. Limited Impact of HER2 Expression on Survival Outcomes in Patients with Intrahepatic Cholangiocarcinoma After Surgical Resection. Hori Y, Yoh T, Seo S, Minamiguchi S, Haga H, Taura K. Oncologist. 2021 Jun 27. doi: 10.1002/onco.13884. Online ahead of print.
  4. A systematic review of prediction models for post-hepatectomy liver failure in patients undergoing liver surgery. Yoshino K, Yoh T, Taura K, Seo S, Ciria R, Briceño-Delgado J. HPB (Oxford). 2021 May 19:S1365-182X(21)00141-6. doi: 10.1016/j.hpb.2021.05.002. Online ahead of print.
  5. Quantitative assessment of microvascular invasion in hepatocellular carcinoma using preoperative serological and imaging markers. Yoh T, Seo S, Ogiso S, Morino K, Fukumitsu K, Ishii T, Nakamoto Y, Taura K. HPB (Oxford). 2021 Jul;23(7):1039-1045. doi: 10.1016/j.hpb.2020.10.024
  6. Proposed Definition for Oligometastatic Recurrence in Biliary Tract Cancer Based on Results of Locoregional Treatment: A Propensity-Score-Stratified Analysis. Morino K, Seo S, Yoh T, Fukumitsu K, Ishii T, Taura K, Morita S, Kaido T, Uemoto S. Ann Surg Oncol. 2020 Jun;27(6):1908-1917. doi: 10.1245/s10434-020-08207-0.
  7. Surgery for Recurrent Hepatocellular Carcinoma: Achieving Long-term Survival. Yoh T, Seo S, Taura K, Iguchi K, Ogiso S, Fukumitsu K, Ishii T, Kaido T, Uemoto S. Ann Surg. 2021 Apr 1;273(4):792-799. doi: 10.1097/SLA.0000000000003358.
  8. The Efficacy and Limitations of Postoperative Adjuvant Chemotherapy in Patients With Extrahepatic Cholangiocarcinoma. Morino K, Seo S, Yoh T, Nishino H, Yamanaka K, Fukumitsu K, Ishii T, Taura K, Okajima H, Kaido T, Uemoto S. Anticancer Res. 2019 Apr;39(4):2155-2161. doi: 10.21873/anticanres.13329.
  9. Reappraisal of Prognostic Impact of Tumor SUVmax by 18F-FDG-PET/CT in Intrahepatic Cholangiocarcinoma. Yoh T, Seo S, Morino K, Fuji H, Ikeno Y, Ishii T, Taura K, Nakamoto Y, Higashi T, Kaido T, Uemoto S. World J Surg. 2019 May;43(5):1323-1331. doi: 10.1007/s00268-019-04917-z.
  10. The Relationship Between 18F-FDG Uptake on PET/CT and Markers of Systemic Inflammatory Response in Patients Undergoing Surgery for Intrahepatic Cholangiocarcinoma. Seo S, Yoh T, Morino K, Fuji H, Taura K, Fukumitsu K, Ishii T, Nakamoto Y, Kaido T, Uemoto S. Anticancer Res. 2019 Jan;39(1):341-346. doi: 10.21873/anticanres.13117.
  11.  Serum Nardilysin, a Surrogate Marker for Epithelial-Mesenchymal Transition, Predicts Prognosis of Intrahepatic Cholangiocarcinoma after Surgical Resection. Yoh T, Hatano E, Kasai Y, Fuji H, Nishi K, Toriguchi K, Sueoka H, Ohno M, Seo S, Iwaisako K, Taura K, Yamaguchi R, Kurokawa M, Fujimoto J, Kimura T, Uemoto S, Nishi E. Clin Cancer Res. 2019 Jan 15;25(2):619-628. doi: 10.1158/1078-0432.CCR-18-0124.
  12. Optimal introduction of laparoscopic liver resection for Child-Pugh B. Fuji H, Seo S, Toda R, Yoh T, Ikeno Y, Fukumitsu K, Ishii T, Taura K, Hatano E, Kaido T, Uemoto S. Asian J Endosc Surg. 2019 Jul;12(3):287-293. doi: 10.1111/ases.12634.
  13. Usefulness of Preoperative 18F-FDG-PET in Detecting Invasive Intraductal Papillary Neoplasm of the Bile Duct. Ikeno Y, Seo S, Yamamoto G, Nakamoto Y, Uemoto Y, Fuji H, Yoshino K, Yoh T, Taura K, Uemoto S. Anticancer Res. 2018 Jun;38(6):3677-3682. doi: 10.21873/anticanres.12645.
  14. Preoperative criterion identifying a low-risk group for lymph node metastasis in intrahepatic cholangiocarcinoma. Yoh T, Hatano E, Seo S, Terajima H, Uchida Y, Taura K, Yasuchika K, Uemoto S. J Hepatobiliary Pancreat Sci. 2018 Jun;25(6):299-307. doi: 10.1002/jhbp.552.
  15. Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by 18F-FDG-PET is associated with the KRAS mutation status and prognosis. Ikeno Y, Seo S, Iwaisako K, Yoh T, Nakamoto Y, Fuji H, Taura K, Okajima H, Kaido T, Sakaguchi S, Uemoto S. J Transl Med. 2018 Apr 11;16(1):95. doi: 10.1186/s12967-018-1475-x.
  16. CAAT/enhancer binding protein-homologous protein deficiency attenuates liver ischemia/reperfusion injury in mice. Wada S, Hatano E, Yoh T, Nakamura N, Okuda Y, Okuno M, Kasai Y, Iwaisako K, Seo S, Taura K, Uemoto S. Liver Transpl. 2018 May;24(5):645-654. doi: 10.1002/lt.25053.
  17. Long-Term Survival of Recurrent Intrahepatic Cholangiocarcinoma: The Impact and Selection of Repeat Surgery. Yoh T, Hatano E, Seo S, Okuda Y, Fuji H, Ikeno Y, Taura K, Yasuchika K, Okajima H, Kaido T, Uemoto S. World J Surg. 2018 Jun;42(6):1848-1856. doi: 10.1007/s00268-017-4387-7.
  18. Proposal of a New Preoperative Prognostic Model for Solitary Hepatocellular Carcinoma Incorporating 18F-FDG-PET Imaging with the ALBI Grade. Yoh T, Seo S, Ogiso S, Kawai T, Okuda Y, Ishii T, Taura K, Higashi T, Nakamoto Y, Hatano E, Kaido T, Uemoto S. Ann Surg Oncol. 2018 Feb;25(2):542-549. doi: 10.1245/s10434-017-6262-z.
  19. Necrostatin-7 suppresses RANK-NFATc1 signaling and attenuates macrophage to osteoclast differentiation. Fuji H, Ohmae S, Noma N, Takeiri M, Yasutomi H, Izumi K, Ito M, Toyomoto M, Iwaki S, Takemoto K, Seo S, Taura K, Hida S, Aoyama M, Ishihama Y, Hagiwara M, Takeda N, Hatano E, Iwaisako K, Uemoto S, Asagiri M. Biochem Biophys Res Commun. 2018 Sep 5;503(2):544-549. doi: 10.1016/j.bbrc.2018.05.153.
  20. Clinical Practice of Postoperative Adjuvant Chemotherapy in Patients with Colorectal Liver Metastases: Impact of the Completion for Six Months. Nishino H, Hatano E, Okuno M, Toda R, Seo S, Taura K, Horimatsu T, Kanai M, Hasegawa S, Matsumoto S, Sakai Y, Uemoto S. Am Surg. 2019 Feb 1;85(2):e111-e114.
  21. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study. Nakamura N, Hatano E, Iguchi K, Sato M, Kawaguchi H, Ohtsu I, Sakurai T, Aizawa N, Iijima H, Nishiguchi S, Tomono T, Okuda Y, Wada S, Seo S, Taura K, Uemoto S, Ikegawa M. BMC Cancer. 2019 Jun 25;19(1):621. doi: 10.1186/s12885-019-5825-8.